Genethon’s
partnership
strategy

In order to accelerate the development of its therapies and their availability to patients, Genethon regularly forms partnerships with pharmaceutical laboratories and biotechs who can provide additional expertise and necessary resources.

Our partnership strategy

A laboratory created by a patient association, Genethon is particularly concerned with ensuring that the treatments derived from its research are accessible to those that need them. This is why we strive to work with partners that share our values. Find out more about our commitment.

To accelerate the development of its programs, Genethon employs a 3-pronged partnership strategy, with one goal, namely to innovate and work with other world leaders in gene therapy in order to make treatments avaialable to patients as quickly as possible.

Collaboration on new or existing gene therapy programs. See the list of current programs.

Collaboration to accelerate the development of new technologies ; Capsid engineering, immuno-modulation approaches, disruptive bioprocess innovation.
Creation of a spin-off for specific projects, which represents an opportunity to partner or to invest for future partners.
- The spin-off Atamyo was created in 2020. Its purpose is to develop gene therapy treatments for neuromuscular indications.

For any questions about our programs or our partnership strategy